Anticoagulant recalled after failed test

August 4, 2026 - 03:00

A new recall has been issued for several lots of dabigatran etexilate capsules, a direct oral anticoagulant commonly prescribed to lower the risk of stroke and dangerous blood clots in patients with heart conditions. The action follows a failed quality test that raised concerns about the product's potency and consistency.

The affected medication, often used by people with atrial fibrillation, works by blocking a key clotting factor in the blood. For patients who rely on it daily, any variation in strength could mean the difference between adequate protection and a serious event like a stroke or pulmonary embolism. The company behind the recall has not disclosed exactly which test failed, but standard checks typically measure dissolution, impurity levels, or the uniformity of the active ingredient across a batch.

Patients currently taking the medication are urged to check their prescription bottle for the specific lot numbers listed in the recall notice. Pharmacists and doctors have been alerted to stop dispensing the affected batches and to arrange replacements with an alternative supply. Health officials stress that patients should not stop taking the drug on their own, as suddenly interrupting anticoagulant therapy can trigger a rebound effect that increases clotting risk.

The recall is classified as a voluntary action, and no adverse events linked to the affected lots have been reported so far. Still, the manufacturer is asking wholesalers and retailers to return any remaining stock. For most patients, the disruption will be brief, but the incident highlights how even routine quality checks can uncover problems that require immediate corrective action. Anyone with questions should contact their prescriber or pharmacy for guidance on switching to a different lot or an alternative anticoagulant.